Sign In
Buy CODX
$1.44
-0.120 (-7.69%)
At Close: Jul 31, 2026
Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript
09:30pm, Thursday, 09'th May 2024
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Br
Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results
04:01pm, Thursday, 09'th May 2024
SALT LAKE CITY , May 9, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx," or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of mo
Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast
09:30am, Thursday, 25'th Apr 2024
SALT LAKE CITY , April 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan
09:30am, Wednesday, 24'th Apr 2024
SALT LAKE CITY , April 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
09:30am, Friday, 12'th Apr 2024
Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries SALT LAKE CITY , April 12, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
09:30am, Thursday, 04'th Apr 2024
SALT LAKE CITY , April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development o
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address
09:30am, Thursday, 21'st Mar 2024
Presentation included announcement of the opening of the new manufacturing facility in Salt Lake City, UT SALT LAKE CITY, March 21, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Compa
Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England
09:30am, Monday, 18'th Mar 2024
SALT LAKE CITY, Utah , March 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the developm
Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
09:19pm, Thursday, 14'th Mar 2024
Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
04:01pm, Thursday, 14'th Mar 2024
SALT LAKE CITY , March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test
09:30am, Thursday, 07'th Mar 2024
The clinical laboratory real-time PCR multiplex test was designed using Co-Dx Co-Primers™ and licensed by the CDSCO for use in diagnostic procedures SALT LAKE CITY , March 7, 2024 /PRNewswire/ -- Co
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast
09:30am, Thursday, 29'th Feb 2024
SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024
09:30am, Thursday, 01'st Feb 2024
SALT LAKE CITY , Feb. 1, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro
09:30am, Wednesday, 27'th Dec 2023
The Company's Emergency Use Authorization submission is for the new Co-Dx PCR Pro instrument and COVID-19 test kit, designed for point-of-care and at-home. The menu of tests in development for the pla
Co-Diagnostics, Inc. (CODX) Q3 2023 Earnings Call Transcript
07:59pm, Thursday, 09'th Nov 2023
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chief Executive Officer B
